Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hitomi Mori

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Breast Cancer (Tokyo, Japan)|January 8, 2020
Microsatellite instability in Japanese female patients with triple-negative breast cancerKanako Kurata, Makoto Kubo, Masaya Kai, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 17, 2026
[A Case of Hormone Receptor-Positive, HER2-Negative Metastatic Recurrent Breast Cancer Successfully Treated with Capivasertib and Fulvestrant in Late-Line Therapy]Masami Hattori, Hitomi Mori, Torakichi Shingo, et al.
Oncotarget|January 21, 2017
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancerHitomi Mori, Makoto Kubo, Rin Yamaguchi, et al.
Plos One|December 16, 2016
BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast CancerHitomi Mori, Makoto Kubo, Reiki Nishimura, et al.
Breast Cancer Research and Treatment|May 10, 2019
T-bet<sup>+</sup> lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancerHitomi Mori, Makoto Kubo, Masaya Kai, et al.
Journal of Mammary Gland Biology and Neoplasia|July 17, 2024
Perimenopausal and Menopausal Mammary Glands In A 4-Vinylcyclohexene Diepoxide Mouse ModelKohei Saeki, Desiree Ha, Gregory Chang, et al.
Cancer Medicine|January 16, 2021
Validity of the prognostication tool PREDICT version 2.2 in Japanese breast cancer patientsKaren Zaguirre, Masaya Kai, Makoto Kubo, et al.
Cancer Medicine|December 4, 2020
Comprehensive molecular profiling broadens treatment options for breast cancer patientsHitomi Kawaji, Makoto Kubo, Nami Yamashita, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Breast Cancer (Tokyo, Japan)|January 8, 2020
Microsatellite instability in Japanese female patients with triple-negative breast cancerKanako Kurata, Makoto Kubo, Masaya Kai, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 17, 2026
[A Case of Hormone Receptor-Positive, HER2-Negative Metastatic Recurrent Breast Cancer Successfully Treated with Capivasertib and Fulvestrant in Late-Line Therapy]Masami Hattori, Hitomi Mori, Torakichi Shingo, et al.
Oncotarget|January 21, 2017
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancerHitomi Mori, Makoto Kubo, Rin Yamaguchi, et al.
Plos One|December 16, 2016
BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast CancerHitomi Mori, Makoto Kubo, Reiki Nishimura, et al.
Breast Cancer Research and Treatment|May 10, 2019
T-bet<sup>+</sup> lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancerHitomi Mori, Makoto Kubo, Masaya Kai, et al.
Journal of Mammary Gland Biology and Neoplasia|July 17, 2024
Perimenopausal and Menopausal Mammary Glands In A 4-Vinylcyclohexene Diepoxide Mouse ModelKohei Saeki, Desiree Ha, Gregory Chang, et al.
Cancer Medicine|January 16, 2021
Validity of the prognostication tool PREDICT version 2.2 in Japanese breast cancer patientsKaren Zaguirre, Masaya Kai, Makoto Kubo, et al.
Cancer Medicine|December 4, 2020
Comprehensive molecular profiling broadens treatment options for breast cancer patientsHitomi Kawaji, Makoto Kubo, Nami Yamashita, et al.
Pageof 3